Dendreon Execs Can't Escape Class Suit Over Stock Sales

Law360, Los Angeles (January 2, 2014, 6:29 PM EST) -- A Delaware judge on Tuesday refused to dismiss a shareholder derivative suit against Dendreon Corp. executives, ruling it sufficiently alleged that the executives may have had nonpublic information about marketing issues with the firm's prostate cancer drug Provenge when they sold their company stock.

Rejecting defendants' claim that the suit failed to make demand, Vice Chancellor Donald F. Parsons Jr. said it provided enough evidence that the 10 executives and officers named in the suit — including former President and CEO Mitchell H. Gold — may...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.